Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of combination of dronedarone hydrochloride and 5-fluorouracil in preparation of antitumor drugs

A dronedarone hydrochloride and anti-tumor drug technology, applied in the field of biomedicine, can solve the problems of low early diagnosis rate, poor prognosis of patients, and side effects

Pending Publication Date: 2022-01-14
THE FIRST AFFILIATED HOSPITAL OF ARMY MEDICAL UNIV +1
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although surgical resection and effective adjuvant treatment at the early stage of the disease have good therapeutic effects, lung cancer is still a threat to patients due to poor prognosis and low early diagnosis rate, and severe side effects of radiotherapy and chemotherapy on the body. A major cancer of life and health

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of combination of dronedarone hydrochloride and 5-fluorouracil in preparation of antitumor drugs
  • Application of combination of dronedarone hydrochloride and 5-fluorouracil in preparation of antitumor drugs
  • Application of combination of dronedarone hydrochloride and 5-fluorouracil in preparation of antitumor drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Cell Proliferation Assay

[0028] Take human liver cancer cells HepG2, PLC / PRF / 5, Hep3B, human lung cancer cells SPC-A1, A549 and mouse lung cancer cells Lewis in the logarithmic phase growth, according to 5×10 3 Cells / well were seeded in 96 wells and cultured in 100 μl DMEM high-glucose medium containing 10% FBS per well, placed in 5% CO 2 , and cultured overnight in a 37°C cell culture incubator. Add dronedarone hydrochloride, 100 μM 5-fluorouracil, and 10 μM dronedarone hydrochloride + 100 μM 5-fluorouracil at final concentrations of 5 μM, 10 μM, and 20 μM, respectively. Add an equal volume of DMSO to the control group, and add 100 μl DMEM to each well. High glucose medium. placed in 5% CO 2 , and cultured in a cell culture incubator at 37°C for 24 hours. Add 10 μl of CCK-8 solution to each well. Continue incubation for 0.5 h in the cell incubator. Absorbance was measured at 450 nm. Calculation formula: cell viability=[(experimental well-blank well) / (control w...

Embodiment 2

[0031] Dronedarone Hydrochloride Treats Liver Cancer Xenografted Tumor Mouse Model

[0032] According to the results of previous cell experiments, the dosage ratio of dronedarone hydrochloride and 5-fluorouracil was selected to be 1:1.5, and the ability to inhibit tumor proliferation was detected at the in vivo level. Take the human liver cancer cell Huh7 growing in the logarithmic phase, and make a cell suspension, containing 1×10 per microliter 4 cells. Inject 100 μl of cell suspension subcutaneously on the back of nude mice, and when the tumor grows to 15 mm, the tumor-bearing mice are randomly divided into three groups. One group is the solvent control group (normal saline containing 5% DMSO), and the second group is the dronedarone hydrochloride combined with 5-fluorouracil group (20mg / kg dronedarone hydrochloride, 30mg / kg 5-fluorouracil, dronedarone hydrochloride Dronedarone hydrochloride was dissolved in normal saline containing 5% DMSO), and the three groups were 5-f...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of combination of dronedarone hydrochloride and 5-fluorouracil in preparation of antitumor drugs. Pharmacodynamic experiments prove that the combination of dronedarone hydrochloride and 5-fluorouracil can effectively inhibit proliferation of human hepatoma cell lines HepG2, PLC / PRF / 5 and Hep3B. The single use of dronedarone hydrochloride can effectively inhibit the proliferation of human hepatoma cell lines HepG2, PLC / PRF / 5 and Hep3B, and the single use of dronedarone hydrochloride can effectively inhibit the proliferation of human lung cancer cell lines SPC-A1 and A549 and mouse lung cancer cell lines Lewis. In addition, dronedarone hydrochloride is combined with 5-fluorouracil, so that growth of tumors in a mouse liver cancer transplantation tumor model can be inhibited. The dronedarone hydrochloride combined antitumor drug has the characteristics of safety, effectiveness and the like when being used for treating liver cancer and lung cancer, can be used for preparing the drug for treating liver cancer and lung cancer, and provides a new treatment strategy for clinical treatment of liver cancer and lung cancer.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the application of dronedarone hydrochloride combined with 5-fluorouracil in the preparation of drugs for treating liver cancer and lung cancer. Background technique [0002] Liver cancer is a common malignant tumor of the digestive system, and the number of liver cancer patients in China accounts for about half of the world's total. There are about 841,000 new liver cancer patients and 782,000 liver cancer deaths every year. China is a big country with liver cancer. The incidence rate of liver cancer in my country is 26.92 / 100,000, and the mortality rate is 23.72 / 100,000. The morbidity and mortality of liver cancer rank fourth and second respectively among malignant tumors in my country. Liver cancer has the characteristics of difficult early diagnosis, rapid progress, and poor prognosis. The overall five-year survival rate of liver cancer in my country is only 12.5%, which seriousl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/513A61K31/343A61P35/00A61P1/16A61P11/00
CPCA61K31/513A61K31/343A61P35/00A61P1/16A61P11/00A61K2300/00
Inventor 柴进张晓珣潘琼瞿家权谭雅江忠勇赵楠
Owner THE FIRST AFFILIATED HOSPITAL OF ARMY MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com